ZA934969B - Isoxazole derivatives for the treatment of irritable Bowel Syndrome - Google Patents

Isoxazole derivatives for the treatment of irritable Bowel Syndrome

Info

Publication number
ZA934969B
ZA934969B ZA934969A ZA934969A ZA934969B ZA 934969 B ZA934969 B ZA 934969B ZA 934969 A ZA934969 A ZA 934969A ZA 934969 A ZA934969 A ZA 934969A ZA 934969 B ZA934969 B ZA 934969B
Authority
ZA
South Africa
Prior art keywords
bowel syndrome
irritable bowel
treatment
isoxazole derivatives
isoxazole
Prior art date
Application number
ZA934969A
Other languages
English (en)
Inventor
Jaswant Singh Gidda
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA934969B publication Critical patent/ZA934969B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA934969A 1992-07-17 1993-07-09 Isoxazole derivatives for the treatment of irritable Bowel Syndrome ZA934969B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91628192A 1992-07-17 1992-07-17

Publications (1)

Publication Number Publication Date
ZA934969B true ZA934969B (en) 1995-01-09

Family

ID=25436992

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA934969A ZA934969B (en) 1992-07-17 1993-07-09 Isoxazole derivatives for the treatment of irritable Bowel Syndrome

Country Status (23)

Country Link
US (1) US5434174A (ja)
EP (1) EP0579507B1 (ja)
JP (1) JPH06166620A (ja)
CN (1) CN1049336C (ja)
AT (1) ATE206918T1 (ja)
AU (1) AU666377B2 (ja)
CA (1) CA2100399A1 (ja)
CZ (1) CZ284881B6 (ja)
DE (1) DE69330926T2 (ja)
DK (1) DK0579507T3 (ja)
ES (1) ES2162808T3 (ja)
HK (1) HK1013795A1 (ja)
HU (1) HUT68727A (ja)
IL (1) IL106307A (ja)
MX (1) MX9304205A (ja)
NO (1) NO304054B1 (ja)
PH (1) PH30148A (ja)
PL (1) PL172494B1 (ja)
PT (1) PT579507E (ja)
RU (1) RU2127111C1 (ja)
TW (1) TW232653B (ja)
UA (1) UA27720C2 (ja)
ZA (1) ZA934969B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5962488A (en) 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7684402B2 (en) 2006-05-15 2010-03-23 Faraday Technology Corp. Method and network device for fast look-up in a connection-oriented communication
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339982A1 (en) * 1988-04-28 1989-11-02 Beecham Group Plc Antibiotic compounds
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5158956A (en) * 1990-05-04 1992-10-27 Eli Lilly And Company Method of inhibiting gastric acid secretion with benzodioxanes
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto

Also Published As

Publication number Publication date
JPH06166620A (ja) 1994-06-14
NO932547D0 (no) 1993-07-13
EP0579507B1 (en) 2001-10-17
PT579507E (pt) 2002-02-28
HU9302035D0 (en) 1993-10-28
UA27720C2 (uk) 2000-10-16
ES2162808T3 (es) 2002-01-16
DE69330926T2 (de) 2002-04-11
IL106307A0 (en) 1993-11-15
DE69330926D1 (de) 2001-11-22
HUT68727A (en) 1995-07-28
NO932547L (no) 1994-01-18
CZ284881B6 (cs) 1999-03-17
RU2127111C1 (ru) 1999-03-10
IL106307A (en) 1997-06-10
ATE206918T1 (de) 2001-11-15
CZ137193A3 (en) 1994-11-16
MX9304205A (es) 1995-01-31
PL299690A1 (en) 1994-03-21
US5434174A (en) 1995-07-18
CA2100399A1 (en) 1994-01-18
PH30148A (en) 1997-01-21
CN1111986A (zh) 1995-11-22
TW232653B (ja) 1994-10-21
AU666377B2 (en) 1996-02-08
NO304054B1 (no) 1998-10-19
CN1049336C (zh) 2000-02-16
EP0579507A1 (en) 1994-01-19
HK1013795A1 (en) 1999-09-10
PL172494B1 (pl) 1997-09-30
AU4199393A (en) 1994-01-20
DK0579507T3 (da) 2001-11-12

Similar Documents

Publication Publication Date Title
HK1013795A1 (en) Isoxazole derivatives for the treatment of irritable bowel syndrome
AU4969990A (en) Stabilized sterilizing or disinfecting halogen containing composition, method and apparatus
US4997657B1 (en) Method for improving skin smoothness.
AU7930291A (en) Method and apparatus for dental treatment
AU8351691A (en) Classified-by-field dictionary generating apparatus, machine translation apparatus and machine translation system using these apparatuses
HU9301361D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
NO871493D0 (no) Fremgangsmaate og apparat for undersoekelse av en grunnformasjon som gjennomtrenges av et borehull.
AU641571B2 (en) Method for treating gas and apparatus used therefor
FI945000A0 (fi) Menetelmä (S)-amino-1-substituoitujen pyrrolidiinien valmistamiseksi
AU4407093A (en) Method and apparatus for prostatic treatment
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
EP0641327A4 (en) NOVEL ALPHA-MANNOSIDASE INHIBITORS.
EP0207606A3 (en) Use of pinacidil as an antiasthma agent
ZA912369B (en) Veterinary treatment
GB9321210D0 (en) Method and apparatus of operating powered devices,for example,automatic doors
AU4871490A (en) Method of treatment using 18-cyanoprogesterone derivatives
AU8854891A (en) Laser apparatus for periodontal treatment
AU1369488A (en) Method and apparatus for the treatment of surfaces of machine components
AU5698690A (en) Method of treatment using 17 beta-cyclopropylaminoandrostene derivatives
ITRM920002A1 (it) Procedimento per il trattamento disinquinante, di residui contenenti caprolattame.